Frontlight ResearchEarly access
Fatty liver disease (MASLD/MASH) trials in Kazakhstan
1 of 3 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleClinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
- Where
- Aktau, Aktobe, Almaty, Astana, Shymkent
- Age
- 18 years to 65 years
- People
- 420
- Run by
- Kazakh Association of Internal Medicine Specialists
See details and how to joinNCT07889999